TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amur Minerals ( (GB:CRTX) ) has shared an update.
CRISM Therapeutics Corporation held its first AGM since its reverse takeover of Amur Minerals and subsequent AIM listing. The company highlighted key achievements, including the submission of a Clinical Trial Authorisation application for its ChemoSeed technology, a significant milestone in its development. The company also secured a grant from Innovate UK for ChemoSeed’s pre-clinical development for prostate cancer, signaling a new market opportunity. CRISM aims to gain trial approval from the MHRA for glioblastoma treatment and plans to begin patient dosing in early 2026, while continuing to validate its innovative delivery method.
More about Amur Minerals
CRISM Therapeutics Corporation is an innovative UK-based company specializing in drug delivery technology aimed at enhancing the clinical performance of cancer treatments for solid tumors. Their primary product, ChemoSeed, is designed for localized delivery of chemotherapy drugs directly into tumors or resection margins, particularly for hard-to-treat cancers like glioblastoma.
Average Trading Volume: 54,093
Technical Sentiment Signal: Sell
Current Market Cap: £4.2M
See more insights into CRTX stock on TipRanks’ Stock Analysis page.